Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof
申请人:NANJING SANHOME PHARMACEUTICAL CO., LTD.
公开号:US10077258B2
公开(公告)日:2018-09-18
The present invention belongs to the field of medicinal chemistry, and relates to substituted pyrimidine compounds as phosphatidylinositol 3-kinase (PI3K) δ inhibitor and a use thereof. In particular, the present invention provides a compound as shown by formula I or an isomer, pharmaceutically acceptable salt, solvate or prodrug thereof, the preparation methods of same and pharmaceutical compositions containing these compounds and a use of these compounds or compositions for treating cancer, hyperblastosis diseases or inflammatory diseases. The compounds of the present invention have a good inhibiting activity on PI3Kδ and have a high selectivity. It is hoped that these will be therapeutic agents for cancer, hyperblastosis diseases or inflammatory diseases.
本发明属于药物化学领域,涉及作为磷脂酰肌醇3-激酶(PI3K)δ抑制剂的取代嘧啶化合物及其用途。特别是,本发明提供了一种如式 I 所示的化合物或其异构体、药学上可接受的盐、溶液或原药、其制备方法和含有这些化合物的药物组合物,以及这些化合物或组合物治疗癌症、增生性疾病或炎症性疾病的用途。本发明的化合物对 PI3Kδ 具有良好的抑制活性,并具有较高的选择性。希望这些化合物能成为治疗癌症、增生性疾病或炎症性疾病的药物。